Swedish med-tech and healthcare company Geras Solutions is one of the most exciting companies in dementia and Alzheimer’s diagnostics.
They are unique in the world in enabling early diagnosis through fully cognitive assessments digitally – from home. Dementia currently affects more than 50 million people worldwide and the number is increasing rapidly as the population ages.
Healthcare systems have long struggled with limited capacity, poor patient access and lack of continuity.
The recent news of significant breakthroughs in the treatment of Alzheimer’s disease also brings new demands on health systems.
The need to ensure that treatable patients are identified in a timely manner, while coping with the increased demand for assessments from people suffering from memory loss, is more urgent than ever.
Gunilla Oswald, CEO of BioArctic, the company behind the new Lecanumab treatment, said of Geras Solutions: – The introduction of disease-modifying therapies will bring new hope to patients suffering from Alzheimer’s disease.
Early detection through digital cognitive tests and blood-based biomarkers will be crucial, and all stakeholders who can offer a new way to improve quality, efficiency and patient access have an important role to play. Geras Solutions’ platform is now being implemented by both public and private healthcare providers.
The company also launches the world’s first digital memory clinic, which is now receiving state reimbursement in Sweden as of mid-October.
Geras Solutions is now opening a €1.5 million seed round to intensify go-to-market and scale up operations.  If there is interest in participating in this round, please contact: Rickard Forsman, Founder and CEO of Geras Solutions [email protected] See pitch for Geras solution here